A Programmatic Approach to Prostate Cancer Screening

Bannakij LojanapiwatThailand Moderator PSA Kinetics Following PADT in mHSPC. Is It a Real-World Tool for Predicting Oncologic Outcome?PSA Kinetics following Primary Androgen Deprivation Therapy (PADT) in mHSPC. Is it a Real-world Tool for Prediction Oncologic Outcome? Bannakij Lojanapiwat, M.D. Professor of Urology, Chiang Mai University, Thailand. Of recent guidelines, upfront primary androgen deprivation monotherapy or combination therapy (PADT) is recommended for the treatment of metastatic hormone sensitive prostate cancer (mHSPC). Limitation of real-world treatment such as culture difference, financial barrier, geographic access to treatment and high operation/ radiation risks associated with medical comorbidity led to underutilization of combination therapy as the standard guideline. Prognostic factors are important in clinical practice which can predict the clinical outcome that offer the pre-treatment counseling for patients to select the optimal treatment. Prostate specific antigen (PSA) levels is one of the important key prognostic markers. PSA kinetics of nadir PSA level and time to nadir PSA following the treatment are the important role for progression to CRPC and oncologic outcome. Our study and the previous studies reported better oncologic outcome especially overall survival, cancer specific survival and time to developed CRPC in mHSPC patients received upfront PADT who decline PSA≥95% (deep responder), PSA nadir ≤ 0.2 ng/ml (low PSA nadir level), time to PSA nadir ≥ 6 month and PSA decline velocity <11 ng/ml/month. PSA Kinetics following Primary Androgen Deprivation Therapy (PADT) is one of a real-world tool for prediction oncologic outcome in the treatment of mHSPC.

David PensonUnited States Speaker Comparison of Various Treatment Options for Localized Prostate CancerThere are numerous therapeutic strategies used to treat localized prostate cancer, each with unique advantages and disadvantages. Furthermore, prostate cancer itself is heterogeneous with some tumors being indolent and others being more aggressive. We will from the presentation by looking at outcomes separately in patients with favorable prognosis and those with unfavorable prognosis, based upon baseline clinical characteristics. We will first compare cancer control and mortality outcomes amongst the various options. We will then present data on patient-reported outcomes. At the conclusion of the presentation, attendees will have a better understanding of outcomes following treatment for localized prostate cancer and will be better prepared to counsel patients newly diagnosed with this common malignancy.Updates on Combination Therapy for Advanced Prostate CancerOver the past decade, there are have been significant advances in the treatment of metastatic prostate cancer. Randomized clinical trial data have demonstrated that combination therapies are superior to monotherapy in terms of cancer control and survival. Various treatment options will be discussed for metastatic castrate-sensitive and -resistant prostate cancer. These will be compared in terms of efficacy and side effect profiles to aid in treatment selection in this The Startup of An Academic Urologist - How to Build up Your Team in Clinical ResearchMany young academic urologists wish to perform clinical research at their institution. Often, however, this is challenging due to lack of resources or time. In this presentation, we will discuss how to build a clinical research program, including identifying what types of individuals need to be part of the team and what sort of resources are required for success. While American examples will often be used, information from this presentation will still be applicable globally.A Programmatic Approach to Prostate Cancer ScreeningProstate cancer screening has advanced beyond annual PSA testing. We now have numerous tools available to aid in identifying men at risk for harboring clinically significant prostate cancer, including MRI and various novel biomarkers. In this presentation, we will review these modalities and lay out a systematic approach to screening in 2025.